Application of glucagon like peptide-1 receptor agonists in the treatment of polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is one of the most common reproductive endocrine diseases of women in reproductive age. In recent years, the advent of glucagon like peptide-1 (GLP-1) receptor agonists is an important medical progress. Such drugs can promote insulin secretion and islet beta cell growth, inhibit appetite, slow down gastric emptying, reduce weight and improve insulin resistance (IR). What’s more, it can adjust menstrual cycles, sex hormone disorders and increase the pregnancy rate of PCOS patients. As a result, they are gradually applied to the treatment of PCOS. Currently, the most frequent used drugs include liraglutide and exenatide. A number of studies have confirmed there are positively curative effects, both the monotherapy and the combining way with metformin. This article reviews the clinical application of GLP-1 receptor agonists in PCOS. Key words: Glucagon-like peptide-1; Glucagon like peptide-1 receptor agonists; Polycystic ovary syndrome; Insulin resistence